Unresectable Lung Non-Small Cell Carcinoma Clinical Trials

20 clinical trials for Unresectable Lung Non-Small Cell Carcinoma across international registries, including 5 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer — RECRUITING · PHASE1
• Papaverine in Combination With Chemoradiation for the Treatment of Stage II-III Non-small Cell Lung Cancer — RECRUITING · PHASE1
• Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors — RECRUITING · PHASE1
• LOTUS-CC: An Observational Research Study to Uncover Subtypes of Cancer Cachexia — RECRUITING
• A Phase II Trial to Evaluate the Efficiency and Safety of Serplulimab Plus Chemotherapy as Conversion Therapy in NSCLC — RECRUITING · PHASE2
• Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer — ACTIVE_NOT_RECRUITING · PHASE3
• CIMAvax Vaccine, Nivolumab, and Pembrolizumab in Treating Patients With Advanced Non-small Cell Lung Cancer or Squamous Head and Neck Cancer — ACTIVE_NOT_RECRUITING · PHASE1
• Trametinib and Pembrolizumab in Treating Patients With Recurrent Non-small Cell Lung Cancer That Is Metastatic, Unresectable, or Locally Advanced — ACTIVE_NOT_RECRUITING · PHASE1
• Adaptive Radiation Planning for the Reduction of Radiation-Induced Toxicity in Patients With Stage II-IV Non-small Cell Lung Cancer — ACTIVE_NOT_RECRUITING · NA
• Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial — NOT_YET_RECRUITING · PHASE2
• Testing the Combination of MLN4924 (Pevonedistat), Carboplatin, and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Who Have Previously Been Treated With Immunotherapy — ACTIVE_NOT_RECRUITING · PHASE2
• NBTXR3 and Radiation Therapy for the Treatment of Inoperable Recurrent Non-small Cell Lung Cancer — ACTIVE_NOT_RECRUITING · PHASE1
• Ipilimumab and Nivolumab in Combination With Radiation Therapy in Treating Patients With Stage 2-3 Non-small Lung Cancer — ACTIVE_NOT_RECRUITING · PHASE1
• Minnelide and Osimertinib for the Treatment of Advanced EGFR Mutated Non-Small Cell Lung Cancer — ACTIVE_NOT_RECRUITING · PHASE1
• Platinum Doublet Chemotherapy and Proton Beam Radiation Therapy in Treating Patients With Stage II-III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery — COMPLETED · PHASE2
• Supportive Care Intervention (ROAR-LCT) for Patients With Stage IIIA, IIIB, and IV Lung Cancer, ROAR-LCT Trial — COMPLETED · NA
• Testing the Safety of Adding Either Monalizumab (IPH2201) or Oleclumab (MEDI9447) to Durvalumab (MEDI4736) Plus Standard Radiation Therapy for Locally Advanced Non-small Cell Lung Cancer (NSCLC), ARCHON-1 Trial — COMPLETED · PHASE1
• Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies — TERMINATED · PHASE1
• Resiliency Among Older Adults Receiving Lung Cancer Treatment — COMPLETED · NA
• Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies — TERMINATED · PHASE1

Refine this search